Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart M Sprague

Showing results (11-20 of 116) with videos related to

Pageof 12
Sort By:
Expert Opinion on Drug Safety|September 13, 2021
A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemiaStuart M Sprague, Markus Ketteler
Seminars in Dialysis|July 4, 2009
When is Vitamin D contraindicated in dialysis patients?Neenoo Khosla, Stuart M Sprague
Advances in Renal Replacement Therapy|August 31, 2002
Use of vitamin D analogs in chronic renal failureGeorge Kim, Stuart M Sprague
Expert Opinion on Pharmacotherapy|July 10, 2018
Sucroferric oxyhydroxide for the treatment of hyperphosphatemiaStuart M Sprague, Jürgen Floege
Clinical Journal of the American Society of Nephrology : CJASN|May 29, 2020
Secondary Hyperparathyroidism in a Patient with CKDRyyan Hyder, Stuart M Sprague
Current Rheumatology Reports|July 17, 2009
Advances in renal bone disease: osteoporosis and chronic kidney diseaseSara Barnato, Stuart M Sprague
Seminars in Dialysis|April 16, 2016
We Do Too Many Parathyroidectomies for CalciphylaxisSagar U Nigwekar, Stuart M Sprague
Seminars in Dialysis|September 28, 2007
Osteoporosis and chronic kidney diseaseAnca Gal-Moscovici, Stuart M Sprague
Clinical Journal of the American Society of Nephrology : CJASN|November 15, 2008
Role of bone biopsy in stages 3 to 4 chronic kidney diseaseAnca Gal-Moscovici, Stuart M Sprague
Kidney360|December 13, 2024
Tight Phosphate Control in ESKD Patients is Warranted: PRORyan M Song, Stuart M Sprague
Pageof 12

Showing results (11-20 of 116) with videos related to

Sort By:
Pageof 12
Expert Opinion on Drug Safety|September 13, 2021
A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemiaStuart M Sprague, Markus Ketteler
Seminars in Dialysis|July 4, 2009
When is Vitamin D contraindicated in dialysis patients?Neenoo Khosla, Stuart M Sprague
Advances in Renal Replacement Therapy|August 31, 2002
Use of vitamin D analogs in chronic renal failureGeorge Kim, Stuart M Sprague
Expert Opinion on Pharmacotherapy|July 10, 2018
Sucroferric oxyhydroxide for the treatment of hyperphosphatemiaStuart M Sprague, Jürgen Floege
Clinical Journal of the American Society of Nephrology : CJASN|May 29, 2020
Secondary Hyperparathyroidism in a Patient with CKDRyyan Hyder, Stuart M Sprague
Current Rheumatology Reports|July 17, 2009
Advances in renal bone disease: osteoporosis and chronic kidney diseaseSara Barnato, Stuart M Sprague
Seminars in Dialysis|April 16, 2016
We Do Too Many Parathyroidectomies for CalciphylaxisSagar U Nigwekar, Stuart M Sprague
Seminars in Dialysis|September 28, 2007
Osteoporosis and chronic kidney diseaseAnca Gal-Moscovici, Stuart M Sprague
Clinical Journal of the American Society of Nephrology : CJASN|November 15, 2008
Role of bone biopsy in stages 3 to 4 chronic kidney diseaseAnca Gal-Moscovici, Stuart M Sprague
Kidney360|December 13, 2024
Tight Phosphate Control in ESKD Patients is Warranted: PRORyan M Song, Stuart M Sprague
Pageof 12